Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03528642 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Sep 11, 2026 → Dec 1, 2026
See other at-risk trials from National Cancer Institute (NCI)

Record History

The 50 most recent of 181 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Final enrollment: 23 participants (planned 40) Primary completion date changed from estimate of Dec 1, 2026 to Dec 10, 2024 · Completion pushed from Dec 1, 2026 to Sep 18, 2027 · Site details revised at 6 of 25 sites Show 3 more changesShow less
    • Primary completion date changed from estimate of Dec 1, 2026 to Dec 10, 2024
    • Completion pushed from Dec 1, 2026 to Sep 18, 2027
    • Site details revised at 6 of 25 sites
  2. Primary and study completion pushed from Sep 11, 2026 to Dec 1, 2026v180
  3. Study sites revised (25)v179 See this version in full on ClinicalTrials.gov ↗
  4. Study Status, Contacts/Locationsv178
  5. Primary and study completion pushed from May 8, 2026 to Sep 11, 2026v177
  6. 45 versions Re-verified since Feb 4, 2026, no change to tracked fieldsv132-v176
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma. Telaglenastat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving telaglenastat with radiation therapy and temozolomide may work better than surgery, radiation therapy, and temozolomide in treating patients with IDH-mutated diffuse astrocytoma or anaplastic astrocytoma.
Trial Details
NCT Number NCT03528642
Lead Sponsor National Cancer Institute (NCI)
Conditions Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
Enrollment 23 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov